

Competitor Analysis: Janus Kinase (JAK) Inhibitors

<https://marketpublishers.com/r/C8E0D1BCC47EN.html>

Date: May 2012

Pages: 44

Price: US\$ 394.00 (Single User License)

ID: C8E0D1BCC47EN

Abstracts

The present Competitive Intelligence Report about new developments in the pipeline of inhibitors of the janus-associated kinase (JAK) provides a competitor evaluation in the field of active R&D projects from preclinical stages up to marketed JAK Inhibitors as of May 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. The database also contains information about discontinued projects. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

As cytokines play pivotal roles in immunity and inflammation, targeting of cytokines and their receptors represents an effective means of treating such diseases. Janus kinases (JAK) are a small family of receptor-associated kinases, that together with signal transducers and activators of transcription (STAT), provide a rapid signalling pathway for cytokines. Four JAKs have been identified: JAK1, JAK2, JAK3 and tyrosine kinase 2 (Tyk2). JAK3 has attracted much attention as an anti-inflammatory drug target because of its restricted hematopoietic tissue expression and because of its specific association with the common gamma chain of the interleukin-2 (IL-2) receptor which is shared by the receptors for IL-4, IL-7, IL-9, IL-15 and IL-21.

The report includes a compilation of current active projects in research and development of selective and dual- or multi-kinase inhibitors incl. JAK inhibitor, for the treatment of myelofibrosis, polycythemia vera, psoriasis, rheumatoid arthritis and other inflammatory diseases. In addition, the report lists company-specific pipelines of JAK inhibitors. Competitor projects are listed in a tabular format providing information on:

Drug Codes,

Target / Mechanism of Action,

Class of Compound,

Company,

Product Category,

Indication,

R&D Stage and

additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Contents

JAK1 Inhibitors

JAK2 Inhibitors

JAK1/2 Inhibitors

JAK3 Inhibitors

Tyk2 Inhibitors

Pan-JAK Inhibitors

Dual Kinase Inhibitors incl. JAK inhibition

Multi-Kinase Inhibitors incl. JAK inhibition

Not Specified JAK Inhibitors

Corporate R&D Pipelines of JAK Inhibitors

About La Merie

I would like to order

Product name: Competitor Analysis: Janus Kinase (JAK) Inhibitors

Product link: <https://marketpublishers.com/r/C8E0D1BCC47EN.html>

Price: US\$ 394.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C8E0D1BCC47EN.html>